Details of the Drug Combination

General Information of Drug Combination (ID: DCHXD7G)

• Drug Combination Name: K-134 + Cisatracurium
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  K-134 (DMD4OK0): Small molecular drug
  Cisatracurium (DMUZPJ5): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 2.81
  Bliss Independence Score: 2.81
  Loewe Additivity Score: 15.51
  LHighest Single Agent (HSA) Score: 15.54

Molecular Interaction Atlas of This Drug Combination

Indication(s) of K-134

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Phase 2	[2]

K-134 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Phosphodiesterase 3 (PDE3)	TTZCG4L	NOUNIPROTAC	Modulator	[4]

Indication(s) of Cisatracurium

Disease Entry	ICD 11	Status	REF
Muscle spasm	MB47.3	Approved	[3]

Cisatracurium Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Cholinergic receptor unspecific (CHR)	TTUPDWN	NOUNIPROTAC	Antagonist	[5]
Neuronal acetylcholine receptor alpha-2 (CHRNA2)	TTF4E0J	ACHA2_HUMAN	Antagonist	[6]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
• [2] ClinicalTrials.gov (NCT00783081) Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication. U.S. National Institutes of Health.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg. 2012 Feb;55(2):381-389.e1.
• [5] Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92.
• [6] Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.